Evaluation of SYS6005 in Patients With Advanced Malignant Tumor

NCT06958679 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

132

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Malignancies
Solid Tumors

Interventions

DRUG: SYS6005

Sponsor

CSPC Megalith Biopharmaceutical Co.,Ltd.